Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1

Conditions

Ras-mutated Metastatic Colorectal Cancer 1Multiple Myeloma 1Anal Cancer Metastatic 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × reolysin × 90 days × Clear all
NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting
122 enrolled
Gastrointestinal

Anal Cancer Metastatic

NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

NCT07446322 2026-05-05

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Oncolytics Biotech

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Ras-mutated Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡